Abstract
Background: Macrophage migration inhibitory factor (MIF) was firstly described in the 1960s as a pleiotropic cytokine affecting a variety of immune cells. Different physiological functions mainly involving inflammatory reactions such as chemokine-like function and regulating systemic stress responses have been reported.
Objective: In several clinical studies the use of MIF as a biomarker has been investigated promising support for diseases with an inflammatory aspect such as sepsis, systemic infections and autoimmune diseases. This article in detail reviews clinical data and evaluates the function as biomarker focusing on inflammatory and autoimmune diseases.
Conclusion: Recent studies suggest MIF to be a marker for different inflammatory diseases and might serve as therapeutic target in the future.
Keywords: MIF, biomarker, infectious disease, autoimmune disease, cytokine, CD74, CXCR.
Current Medicinal Chemistry
Title:Macrophage Migration Inhibitory Factor - A Favorable Marker in Inflammatory Diseases?
Volume: 25 Issue: 5
Author(s): Johannes Hertelendy, Georg Reumuth, David Simons, Christian Stoppe, Bong-Sung Kim, Jan-Philipp Stromps, Paul C. Fuchs, Jurgen Bernhagen, Norbert Pallua and Gerrit Grieb*
Affiliation:
- Department of Plastic Surgery and Hand Surgery, Burn Center, Medical Faculty, RWTH Aachen University, Pauwelsstrasse 30, 52074 Aachen,Germany
Keywords: MIF, biomarker, infectious disease, autoimmune disease, cytokine, CD74, CXCR.
Abstract: Background: Macrophage migration inhibitory factor (MIF) was firstly described in the 1960s as a pleiotropic cytokine affecting a variety of immune cells. Different physiological functions mainly involving inflammatory reactions such as chemokine-like function and regulating systemic stress responses have been reported.
Objective: In several clinical studies the use of MIF as a biomarker has been investigated promising support for diseases with an inflammatory aspect such as sepsis, systemic infections and autoimmune diseases. This article in detail reviews clinical data and evaluates the function as biomarker focusing on inflammatory and autoimmune diseases.
Conclusion: Recent studies suggest MIF to be a marker for different inflammatory diseases and might serve as therapeutic target in the future.
Export Options
About this article
Cite this article as:
Hertelendy Johannes , Reumuth Georg , Simons David , Stoppe Christian , Kim Bong-Sung , Stromps Jan-Philipp , Fuchs C. Paul , Bernhagen Jurgen , Pallua Norbert and Grieb Gerrit *, Macrophage Migration Inhibitory Factor - A Favorable Marker in Inflammatory Diseases?, Current Medicinal Chemistry 2018; 25(5) . https://dx.doi.org/10.2174/0929867324666170714114200
DOI https://dx.doi.org/10.2174/0929867324666170714114200 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Human Parvovirus B19: An Infectious Agent with the Potential to Induce and Trigger Rheumatic Disease
Current Rheumatology Reviews Recent Developments in the Discovery of Selective Glucocorticoid Receptor Modulators (SGRMs)
Current Topics in Medicinal Chemistry Adverse Effects of Statins - Mechanisms and Consequences
Current Drug Safety Synthetic Peptides Derived from Ribosomal Proteins of Leishmania spp. in Mucocutaneous Leishmaniasis: Diagnostic Usefulness
Protein & Peptide Letters Autoimmunity-Inducing Metals (Hg, Au and Ag) Modulate Mast Cell Signaling, Function and Survival
Current Pharmaceutical Design TNF Superfamily Protein-Protein Interactions: Feasibility of Small- Molecule Modulation
Current Drug Targets Parasites in Rheumatoid Arthritis: Imminent Threat or Protective Effect?
Current Rheumatology Reviews Editorial (Thematic Issues: Heads Or Tails: Betting On CD6 As a Resurged Target For Autoimmune Diseases and Sepsis)
Current Drug Targets Human Fetal Mesenchymal Stem Cells
Current Stem Cell Research & Therapy Genetic Susceptibility to Autoimmune Disorders: Clues from Gene Association and Gene Expression Studies
Current Molecular Medicine B-Cell Based Gene Therapy for Autoimmune Diseases
Infectious Disorders - Drug Targets Ubiquitin Ligases as Key Elements for the Modulation of the Immune Response: An Insight in the Pathogenesis of Autoimmunity
Current Rheumatology Reviews Properdin and Complement Activation: A Fresh Perspective
Current Drug Targets CD24 in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis: Targeting Redundancy for Immunotherapy?
Current Immunology Reviews (Discontinued) Autoimmunity and Apoptosis - Therapeutic Implications
Current Medicinal Chemistry Interferon gama induced Tryptophan Degradation Neuropsychiatric and Immunological Consequences
Current Drug Metabolism Control of Autoimmune Diseases by the B7-CD28 Family Molecules
Current Pharmaceutical Design Immunotherapy-Based Strategies for the Treatment of Autoimmune Diabetes: Searching for the Cure
Current Pharmaceutical Design Targeted Therapies – Many Ways to (the Peace of) Rome
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Under Re-organization) Biologics as Treatment for Systemic Lupus: Great Efforts, Sobering Results, New Challenges
Current Drug Discovery Technologies